Has adagrasib been successfully launched in China?

Adagrasib is a targeted drug targeting KRAS G12C mutations. It is mainly used to treat non-small cell lung cancer (NSCLC) and other tumors related to KRAS G12C mutations. Although adagrasib is approved globally, it has not yet been successfully launched in China. Therefore, Chinese patients cannot purchase the drug directly through formal domestic channels and need to obtain it through overseas channels.

Since adagrasib has not yet been approved in China, patients can only purchase the drug through foreign channels. In overseas markets, especially the United States, the price of the original drug of adagrasib is very high, usually as high as hundreds of thousands of yuan per box. This is a significant burden for many patients, especially if long-term treatment is required, so cost becomes a major consideration.

However, patients can also choose to purchase generic drugs of adagrasibu, especially those from Laos, which are relatively affordable. Take the generic drug of adagrasibu produced in Laos as an example. Its price is about more than 3,000 yuan, which is far lower than the price of the original drug. It is worth noting that generic drugs in Laos are almost identical in composition to original drugs and have similar therapeutic effects, making them an affordable alternative chosen by many patients.

Although generic drugs offer more cost-effective options, patients should still make sure to go through formal channels when purchasing to ensure the quality and efficacy of the medicine. In addition, since adagrasib is not yet available in China, patients need to pay special attention to the import legality and related usage regulations of the drug when purchasing. In general, although the original drug of adagrasiib is more expensive, by choosing generic drugs, patients can reduce the financial burden of drug costs without sacrificing efficacy.

References：https://www.krazati.com/